Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (TEVA) launched LongActingImpact.com, an educational website for healthcare providers focused on long-acting injectables (LAIs) in schizophrenia care, on September 16, 2026.
The site offers information on how LAIs may reduce relapse risk, support treatment adherence and continuity of care, and aid transitions from inpatient to outpatient settings. It includes step-by-step guidance for patient conversations, from clarifying life goals to building trust through ongoing dialogue. Teva describes the platform as part of its commitment to equip clinicians with evidence-based resources that may help people living with schizophrenia have improved, more uninterrupted care.
Teva Pharmaceutical (TEVA) began trading its ordinary shares directly on the New York Stock Exchange on September 14, 2026, completing its transition away from an American Depositary Shares program.
The shares continue to trade under the ticker “TEVA” on both the NYSE and the Tel Aviv Stock Exchange. The company said the direct ordinary share listing is intended to broaden investor access and strengthen its position in U.S. capital markets. Teva highlights a recent return to investment‑grade credit ratings from all three major rating agencies and ongoing debt reduction as evidence of financial transformation.
Under its Pivot to Growth strategy, Teva reports that its three flagship innovative brands AUSTEDO, AJOVY, and UZEDY have grown collectively by more than 40% year‑over‑year year to date, with expected 2026 revenues of approximately $3.7 billion. The company also cites an innovative pipeline with potential of more than $10 billion in peak revenues as it seeks to expand margins, grow earnings, and create long‑term shareholder value.
Teva Pharmaceutical Industries (TEVA) has priced approximately $4.9 billion (equivalent) of new senior notes across five euro- and dollar-denominated tranches to refinance existing debt. The new issues comprise €1.0 billion of 4.250% notes due 2033, €500 million of 4.625% notes due 2036, $1.0 billion of 5.500% notes due 2034, $1.0 billion of 5.750% notes due 2037, and $1.2 billion of 5.250% notes due 2032, issued by Teva Finance II, III and IV and guaranteed on a senior unsecured basis by Teva.
Settlement is expected around September 16, 2026, subject to customary conditions. Teva expects to use net proceeds plus cash on hand to fund conditional redemptions of multiple outstanding series, including all 6.750% notes due 2028, all 7.875% and 7.375% sustainability-linked notes due 2029, up to $450 million of 4.750% sustainability-linked notes due 2027, and up to €1.15 billion of 4.375% sustainability-linked notes due 2030, as well as fees, expenses and general corporate purposes.
Teva (TEVA) plans to issue new euro- and dollar-denominated senior notes through its Dutch finance subsidiaries to refinance existing indebtedness.
Teva expects to use net proceeds, together with cash on hand, to fund conditional redemptions of several outstanding notes, pay related fees and expenses and, if any proceeds remain, for general corporate purposes including further debt repayment. The company intends to redeem all 6.750% Senior Notes due 2028, all 7.875% and 7.375% Sustainability-Linked Senior Notes due 2029, up to $450 million of 4.750% Sustainability-Linked Senior Notes due 2027 and up to €1.25 billion of 4.375% Sustainability-Linked Senior Notes due 2030, subject to completion of the offering. The new notes will be unsecured senior obligations of the issuers, fully and unconditionally guaranteed on a senior basis by Teva.
Teva (TEVA) announced that S&P Global Ratings upgraded its long-term issuer credit rating to BBB- from BB+, with a Stable outlook. With earlier upgrades from Fitch and Moody’s, Teva now holds investment-grade ratings from all agencies that cover its debt, which the company says reflects strong execution, debt reduction and improved financial flexibility.
Teva (TEVA) reported positive topline Phase 2a results for TEV ‘408, its investigational anti-IL-15 monoclonal antibody in adults with celiac disease on a gluten-free diet.
The randomized, placebo-controlled study enrolled 50 participants who received a single subcutaneous dose of TEV ‘408 followed by a six-week daily gluten challenge. The trial met its primary endpoint at week 8, showing statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo, with an LS mean change in villous height-to-crypt depth ratio of -0.43 for TEV ‘408 versus -0.88 for placebo (treatment difference 0.45; 95% CI: 0.06–0.84; p<0.05). The drug also showed a favorable effect on intestinal inflammation, with IEL density increasing 27.60 in placebo versus 0.37 in TEV ‘408 (treatment difference -27.23; 95% CI: -39.67 to -14.79), and demonstrated lower GI symptom scores versus placebo.
TEV ‘408 was well-tolerated with no emerging safety signals. The asset holds FDA Fast Track designation in celiac disease and is also progressing in vitiligo, supported by a funding agreement with Royalty Pharma of up to $500 million to accelerate development.
Teva (NYSE: TEVA) announced that President and CEO Richard Francis will present at three investor conferences in September 2026: the Morgan Stanley Global Healthcare Conference on September 14, the J.P. Morgan U.S. All Stars Conference on September 22, and the BofA Global Healthcare Conference on September 23. Live webcasts and archives will be available via Teva’s Investor Relations website.
Teva (NYSE: TEVA) announced a shared commitment with the Trump Administration to pursue an agreement aimed at lowering costs of select medicines for U.S. Medicaid patients and strengthening supply chain security. The parties are in active discussions, with terms to remain confidential until any final deal is reached.
If completed, the GENEROUS framework would align U.S. Medicaid pricing for certain Teva medicines with leading developed markets, include a prospective Most-Favored-Nation commitment for applicable future innovative launches, and provide a dedicated reserve of selected active pharmaceutical ingredients and continued U.S. manufacturing investment.
Teva (NYSE: TEVA) announced it has agreed to act as stalking horse bidder in a court-supervised Section 363 auction to acquire certain neuroscience assets from BioXcel Therapeutics, including worldwide rights to dexmedetomidine sublingual film (BXCL501/IGALMI) for agitation in adults with schizophrenia or bipolar I/II disorder.
According to Teva, the proposal includes a $57.5 million upfront payment and up to $67.5 million in contingent, time- and sales-based payments linked to FDA approval timing and commercial milestones. The deal is subject to bankruptcy court approval, potential higher bids, and customary closing conditions, and would not involve acquiring BioXcel itself. BXCL501 is under FDA review for potential at-home use, with a PDUFA target date of November 14, 2026, and Teva said the asset aligns with its Pivot to Growth strategy and would expand its psychiatry portfolio if completed and approved.
Teva (NYSE: TEVA) announced that the U.S. FDA has accepted the New Drug Application and granted Priority Review for ecopipam (EBS-101), a first-in-class selective D1 receptor antagonist for pediatric Tourette syndrome, with a targeted PDUFA action date in late Q1 2027.
According to Teva, ecopipam, which has Orphan Drug designation, could become the first new treatment for pediatric Tourette syndrome in over 10 years and the first novel mechanism of action in more than 50 years. The NDA is supported by Phase 2b and Phase 3 data showing statistically significant tic reduction and a 53% decreased relapse risk over 12 weeks versus placebo, with no clinically meaningful changes in weight, metabolic, ECG, movement-disorder, or psychiatric measures and a generally well-tolerated safety profile.